artifici
blood
innov
concept
transfus
medicin
specif
design
compound
perform
task
transport
deliveri
oxygen
bodi
replac
function
allogen
human
blood
transfus
sever
molecul
develop
past
decad
achiev
object
contin
refin
continu
made
quest
ideal
blood
substitut
current
avail
technolog
manufactur
artifici
blood
haemoglobin
obtain
outdat
humanbovin
blood
haemoglobin
base
oxygen
carrier
util
perfluorocarbon
synthet
blood
substitut
advantag
requir
compat
test
free
blood
born
infect
prolong
shelf
life
requir
refriger
artifici
blood
project
signific
impact
develop
medic
care
futur
complement
current
blood
product
transfus
creat
stabl
suppli
safe
effect
product
like
reduc
requir
blood
transfus
drastic
especi
set
trauma
surgeri
therebi
reduc
relianc
bank
donat
blood
phenomen
increas
number
surgic
procedur
elect
emerg
trauma
case
demand
human
blood
transfus
seen
overwhelm
rise
number
unit
collect
blood
donor
insuffici
cope
increas
requir
human
blood
modern
day
medicin
surgeri
demand
addit
donat
human
blood
fraught
concern
relat
short
storag
life
possibl
transmiss
blood
born
infect
allerg
reaction
increas
cost
collect
process
crossmatch
mitig
ever
expand
dispar
demand
suppli
blood
difficulti
associ
store
human
blood
artifici
blood
emerg
promis
option
artifici
blood
serv
provid
substitut
convent
blood
transfus
blood
blood
product
deriv
one
person
infus
anoth
term
artifici
blood
often
use
interchang
blood
surrog
blood
substitut
actual
misnom
artifici
blood
lack
numer
essenti
attribut
human
blood
like
haemostat
process
type
immunolog
defens
bodi
nonetheless
serv
carri
import
function
transport
address
correspond
author
depart
anaesthesia
sanjay
gandhi
post
graduat
institut
medic
scienc
lucknow
india
tel
email
rudrashish
yahoocom
oxygen
carbon
dioxid
throughout
bodi
thu
appropri
term
substanc
red
blood
cell
rbc
substitut
artifici
oxygen
carrier
aoc
quest
suitabl
altern
human
blood
date
back
th
centuri
sir
christoph
wren
suggest
use
ale
wine
opium
blood
substitut
variou
substanc
like
urin
plant
resin
sheep
blood
milk
treatment
asiat
cholera
salt
solut
also
tri
previous
follow
path
break
research
landstein
variou
blood
group
blood
transfus
becam
safer
establish
medic
procedur
understand
oxygen
transport
deliveri
rbc
gradual
improv
necess
type
specif
allogen
transfus
recogn
foundat
develop
artifici
blood
start
laid
earli
amberson
et
al
report
first
infus
cell
free
haemoglobin
patient
postpartum
haemmorhag
resuscit
anim
experi
free
haemoglobin
collect
lyse
red
blood
cell
transfus
unmodifi
product
anim
result
renal
failur
coagulopathi
complement
activ
antigen
histamin
releas
iron
deposit
vasoconstrict
toxic
later
attribut
presenc
red
cell
stroma
product
also
strong
affin
free
haemoglobin
nitric
oxid
potent
vasodil
caus
unoppos
vasoconstrict
pressor
respons
due
nitric
oxid
scaveng
effect
focus
research
develop
field
receiv
impetu
mid
follow
apprehens
caus
possibl
hiv
infect
blood
associ
infecti
diseas
like
hepat
b
hepat
c
west
nile
viru
enceph
coronaviru
human
cell
leukemia
viru
bacteri
infect
blood
transfus
becam
increasingli
recogn
allogen
blood
transfus
also
result
certain
non
infecti
complic
like
haemolyt
transfus
reaction
transfus
relat
acut
lung
injuri
graft
versu
host
reject
anaphylaxi
post
transfus
purpura
amount
donat
store
blood
gradual
unabl
cope
ever
increas
demand
thu
defici
project
year
come
incur
expenditur
collect
store
process
blood
product
also
gradual
rise
cumul
effect
factor
provid
major
boost
develop
artifici
blood
past
decad
main
purpos
substanc
provid
temporari
support
circulatori
system
till
time
bodi
bone
marrow
regener
suffici
rbc
concentr
one
import
function
blood
oxygen
transport
cell
tissu
main
clinic
indic
administr
artifici
blood
includ
trauma
volum
replac
stabil
elect
surgeri
preoper
blood
conserv
form
acut
normovolem
haemodilut
periop
volum
replac
follow
massiv
blood
loss
apart
abl
transport
oxygen
desir
qualiti
artifici
blood
prerequisit
blood
group
cross
match
compat
test
long
shelf
life
prefer
room
temperatur
surviv
circul
substanti
period
intravascular
dwell
time
clear
kidney
absenc
pathogen
advers
effect
abl
effect
deliv
oxygen
tissu
addit
transport
current
strategi
produc
artifici
blood
includ
synthet
product
chemic
isol
recombin
biochem
technolog
convent
blood
substitut
belong
either
two
class
haemoglobin
base
oxygen
carrier
hboc
perfluoro
carbon
pfc
hboc
deriv
haemoglobin
isol
synthet
manufactur
fig
oxygen
bind
coval
compound
natur
occur
haemoglobin
design
fulfil
follow
purpos
inher
decreas
oxygen
affin
increas
tissu
unload
prolong
intravascular
retent
decreas
colloid
osmot
activ
absenc
renal
toxic
sourc
haemoglobin
either
human
obtain
outdat
store
blood
bovin
blood
genet
engin
blood
group
substanc
protein
virus
remov
heat
filtrat
process
haemoglobin
purif
erythrocyt
isol
haemoglobin
subject
molecular
modif
reconstitut
artifici
blood
formula
haemoglobin
natur
form
consist
chain
bound
iron
haem
group
bind
oxygen
manufactur
process
hboc
involv
extract
haemoglobin
thereaft
stabilis
crosslink
tetram
polymer
use
glutaraldehyd
oraffinos
conjug
polyethylen
glycol
encapsul
phospholipid
vesicl
mix
electrolyt
solut
stabilis
hboc
use
cross
link
polymer
larger
molecul
like
polyethylen
glycol
dextran
polyoxyethylen
also
aid
substanti
increas
intravascular
dwell
time
hour
newer
molecul
develop
antioxid
like
superoxid
dismutas
catalas
cross
link
haemoglobin
structur
incorpor
antioxid
help
reduc
sever
ischaem
reperfus
injuri
condit
like
stroke
myocardi
infarct
organ
transplant
base
techniqu
improv
stabil
follow
group
haemoglobin
solut
avail
surfac
modifi
haemoglobin
peg
hb
php
haemospan
produc
attach
larg
molecul
like
polyethylen
glycol
surfac
lysin
group
modif
increas
viscos
oncot
pressur
solut
solut
propens
caus
moder
vasoconstrict
small
size
haemoglobin
molecul
allow
pass
small
vessel
oxygen
area
reach
rbc
thu
use
treatment
patient
stroke
increas
suscept
tumour
cell
radiat
chemotherapi
also
vasopressor
effect
util
treat
hypotens
follow
septic
shock
also
lower
incid
antibodi
product
ii
intramolecular
cross
link
haemoglobin
hemassist
rhb
tetramer
stabil
prevent
renal
filter
accomplish
intermolecular
cross
link
two
two
subunit
use
site
specif
crosslink
cross
link
two
two
chain
cross
link
also
reduc
affin
haemoglobin
oxygen
commonli
use
cross
linker
includ
fumar
dbbf
nfplp
iii
polymeris
haemoglobin
polyhem
hemopur
hemolink
surfac
amino
acid
group
link
reagent
like
glutaraldehyd
neglig
side
effect
note
compound
product
transfus
sever
time
compassion
use
basi
administr
polymer
haemoglobin
patient
undergo
infraren
aortic
reconstruct
shown
avoid
allogen
blood
transfus
patient
iv
liposom
encapsul
haemoglobin
purifi
haemoglobin
reencapsul
stabl
lipid
membran
liposom
made
phospholipid
bilay
cholesterol
molecul
ad
increas
rigid
mechan
stabil
enclos
stroma
free
haemoglobin
solut
diphosphoglycer
inositol
hexaphosph
gelatin
fluid
ad
stabil
ultraviolet
radiat
redox
inhibitor
use
caus
polymer
unsatur
phospholipid
stabilis
also
achiev
coat
liposom
polym
encapsul
haemoglobin
often
call
haemosom
allow
manipul
physiochem
properti
circul
lifetim
p
modifi
haemoglobin
suitabl
alter
modif
liposom
allow
easier
oxygen
unload
oxygen
affin
adjust
co
encapsul
alloster
effector
like
pyridox
often
neg
charg
lipid
capsul
limit
aggreg
encapsul
also
prevent
denatur
haemoglobin
enhanc
biodistribut
modif
polyethylen
glycol
increas
half
life
make
water
solubl
lower
antigen
increas
site
specif
target
sinc
vesicl
made
purifi
haemoglobin
lipid
compat
immun
system
nanocapsul
haemoglobin
made
biodegrad
polym
like
polylactid
develop
polylactid
get
convert
water
carbon
dioxid
bodi
henc
accumul
reticuloendotheli
system
fig
synthet
manufactur
hboc
certain
factor
need
consid
widespread
advocaci
hboc
rbc
exert
colloid
osmot
pressur
wherea
haemoglobin
like
plasma
protein
exert
result
cellular
haemoglobin
alter
intravascular
volum
act
plasma
expand
hboc
circul
half
life
shorter
normal
rbc
major
hboc
remain
circul
around
hour
wherea
whole
blood
transfus
last
day
releas
free
radic
insid
bodi
free
haemoglobin
breakdown
product
like
haem
iron
methaemoglobin
concentr
also
increas
due
oxid
properti
hboc
first
choic
obtain
haemoglobin
outdat
human
blood
limit
suppli
thu
bovin
blood
util
procur
haemoglobin
bovin
haemoglobin
potenti
harbour
prion
pathogen
respons
caus
bovin
spongiform
encephalopathi
creutzfeldtjakob
diseas
overcom
problem
also
ensur
steadi
suppli
haemoglobin
futur
genet
engin
bacteria
produc
recombin
sourc
human
haemoglobin
attempt
recombin
haemoglobin
optro
recombin
dna
technolog
util
produc
modifi
haemoglobin
organ
like
ecoli
yeast
certain
segment
amino
acid
sequenc
human
haemoglobin
replac
prevent
disassoci
dimer
maintain
oxygen
affin
haemoglobin
gene
transfer
use
plasmid
vector
ecoli
cell
express
gene
lead
product
haemoglobin
protein
approach
elimin
concern
relat
diseas
transmiss
haemoglobin
obtain
human
bovin
sourc
high
cost
techniqu
howev
major
hindranc
pfc
chemic
inert
molecul
structur
similar
hydrocarbon
hydrogen
group
replac
fluorin
size
time
smaller
rbc
capabl
carri
oxygen
carbon
dioxid
without
bind
gase
previous
use
provid
oxygen
prematur
infant
respiratori
distress
syndrom
due
insolubl
water
need
emulsifi
addit
lipid
high
pressur
homogen
suspend
tini
particl
pfc
blood
satur
pfc
occur
passiv
molecul
oxygen
dissolv
molecular
caviti
within
liquid
droplet
oxygen
pfc
relat
partial
pressur
oxygen
contact
pfc
therefor
best
result
obtain
patient
breath
oxygen
time
infus
pao
mm
hg
reticuloendotheli
system
respons
system
remov
pfc
exhal
via
lung
result
short
dose
depend
circulatori
half
life
infus
molecul
vapor
exhal
day
pfc
use
initi
disadvantag
accumul
reticuloendotheli
system
score
haemoglobin
base
molecul
follow
count
reactiv
oxygen
gase
increas
oxygen
solubl
plasma
effect
temperatur
ph
diphosphoglycer
dissolut
oxygen
allow
easi
faster
transfer
oxygen
cell
tissu
variabl
carri
capac
depend
upon
fio
pfc
classifi
fig
first
gener
pfc
fluosol
da
prototyp
class
consist
perfluorodecalin
perfluorotrypropylamin
perfluorodecalin
transport
oxygen
perfluorotrypropylamin
provid
stabil
compound
fluosol
approv
fda
blood
substitut
cardiac
surgeri
fulli
oxygen
pfc
infus
coronari
angioplasti
provid
oxygen
deliveri
surgeri
second
gener
pfc
perfluorodecalin
perfluorooctyl
bromid
bi
perfluorobutyl
ethylen
belong
class
oxygen
carri
capac
substanti
higher
first
gener
pfc
excret
faster
lower
tissu
retent
first
gener
pfc
respons
complement
activ
especi
lecithin
base
demonstr
cytotox
phagocyt
cell
like
monocyt
granulocyt
pfc
known
caus
flu
like
symptom
occur
due
opsonis
phagocytosi
pfc
emuls
recipi
organ
immun
system
exposur
high
oxygen
concentr
pfc
infus
result
oxygen
toxic
pfc
also
implic
transient
reduct
platelet
count
begin
day
administr
normal
day
also
pfc
product
use
human
bodi
need
remov
process
requir
around
month
overload
reticuloendotheli
system
suppress
function
retain
organ
histolog
effect
like
appear
enlarg
vacuol
histiocyt
seen
liver
biopsi
higher
rate
neurolog
complic
found
human
cardiac
surgeri
case
faster
better
oxygen
distribut
molecul
allow
full
capac
oxygen
transport
immedi
transfus
store
blood
requir
hour
attain
full
oxygen
carri
capac
due
deplet
diphosphoglycer
higher
extract
rate
ratio
pfc
allow
reach
oxygen
carri
capac
compar
haemoglobin
low
affin
oxygen
allow
rapid
unload
oxygen
tissu
ensur
adequ
oxygen
deliveri
haemoglobin
level
gmdl
without
advers
effect
longer
shelf
life
store
room
temperatur
prolong
period
year
readi
use
compar
store
blood
store
around
day
necess
refriger
product
univers
compat
sinc
protein
compon
remov
human
immun
system
jehovah
wit
religi
group
belief
prohibit
accept
donat
blood
blood
product
due
chemic
natur
pfc
accept
practic
altern
group
fulfil
need
blood
transfus
rapid
advanc
screen
techniqu
donor
blood
reduc
incid
transfus
associ
infect
like
hiv
hepat
nevertheless
gap
increas
demand
human
blood
limit
suppli
continu
widen
moreov
immunolog
effect
blood
transfus
result
increas
wound
infect
delay
heal
progress
malign
diseas
even
though
exist
varieti
artifici
blood
serv
oxygen
transport
deliveri
volum
expans
concurr
usag
blood
salvag
techniqu
significantli
lower
avoid
requir
allogen
blood
transfus
surgic
procedur
hyperox
ventil
combin
small
bolus
pfc
maintain
adequ
tissu
oxygen
intraop
surgeri
anticip
major
blood
loss
clinic
implic
artifici
blood
far
reach
specif
situat
mass
militari
civilian
casualti
war
natur
disast
area
scarciti
safe
blood
transfus
like
south
africa
nigeria
larg
popul
hiv
infect
thu
becom
strong
basi
promot
develop
artifici
blood
blood
substitut
extens
clinic
applic
substanc
current
imped
issu
relat
safeti
cost
lower
intravascular
dwell
time
suffici
suppli
raw
materi
toxic
prolong
tissu
retent
addit
contemporari
blood
substitut
possess
immunolog
clot
properti
essenti
properti
human
blood
therefor
develop
field
prepar
artifici
platelet
white
blood
cell
blood
protein
underway
mitig
shortcom
avail
molecul
ensur
futur
blood
substitut
contain
function
element
develop
lyophil
platelet
infus
platelet
membran
fibrinogen
coat
albumin
microcapsul
encourag
stride
direct
enhanc
procoagul
effect
effect
exist
platelet
patient
thrombocytopenia
upcom
dimens
investig
includ
experiment
stem
cell
product
rbc
specif
rare
group
method
call
blood
pharm
transgen
haemoglobin
transgen
pig
reduc
reject
polyhaemoglobin
enzym
complex
reduct
ischaem
reperfus
injuri
stroke
myocardi
infarct
haemmorhag
shock
transplant
surgeri
artifici
blood
substitut
devoid
share
complic
commonli
observ
side
effect
includ
increas
system
pulmonari
arteri
resist
decreas
cardiac
output
jaundic
increas
activ
enzym
like
amylas
lipas
transaminas
increas
level
reflect
clinic
pancreat
error
interfer
photoelectr
detector
still
specul
clinic
impact
vasoconstrict
activ
blood
substitut
still
unclear
might
deleteri
effect
organ
blood
flow
function
thu
non
vasoact
blood
substitut
prefer
therefor
avail
nonvasoact
hboc
may
desir
maleimideactiv
polyethyleneglycolmodifi
haemoglobin
hemospan
tm
sangart
corp
repres
hboc
featur
low
haemoglobin
concentr
gdl
high
oxygen
affin
mmhg
high
viscos
cp
sizeabl
volum
clinic
trial
systemat
studi
clinic
safeti
efficaci
yet
need
done
artifici
blood
substitut
find
way
regular
practic
recent
literatur
point
toward
newer
vista
therapeut
applic
blood
substitut
clinic
practic
rang
foetal
hypoxia
preeclampsia
cerebr
ishchaemia
liver
transplant
addit
util
contrast
agent
infect
tracer
futur
research
initi
context
therefor
direct
toward
provid
adequ
quantiti
safe
efficaci
commerci
viabl
altern
lesser
drawback
reduc
depend
donat
blood
reduc
mortal
due
transfus
requir
new
avenu
field
transfus
medicin
thu
open
immens
possibl
none
